Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer have?
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer has 1,332 citations in the OpenAlex counts ScholarIQ stores.
When was Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer published?
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer has 2019 year in the ScholarIQ index.
What is the open-access status of Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer?
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer has bronze oa status in the ScholarIQ index.
What is the DOI of Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer?
The DOI for Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer is on the source record.
What is the PMID of Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer?
The PMID for Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer is on the source record.
What is the OpenAlex record for Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer?
The OpenAlex for Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer is on the source record.